Back to search

National and Kapodistrian University of Athens

Αναζήτηση μηχανισμών για την αύξηση της αποτελεσματικότητας της μετφορμίνης ως φαρμακευτική θεραπεία για τον καρκίνο του θυρεοειδούς

Abstract

dc:description

Τhe objective of the current PhD was to identify methods to increase Metformin’s efficacy in vitro. Initially, we examined the expression of the transporter of Metformin OCT1. Despite detecting the transporter, no significant changes were observed in the pathologic characteristics of the patients that were examined and hence we did not proceed to the pharmacologic regulation of OCT1. Next step was targeting cell metabolism, and more specifically the micro-environment and the glucose concentration in the medium. The initial experiments demonstrated that Metformin in low glucose conditions 5mM (which corresponds to normoglycemia in humans – 100 mg/dl) did not only cause inhibition of cell proliferation, but also cell death via oncosis. Oncosis is caused by ATP depletion, which in turn causes activation of AMPK as shown in our study. We next showed that in low glucose conditions, the therapeutic combination of 25 μΜ Metformin and 5mM 2DG caused an apoptotic cell death in thyroid cancer cells, proving that Metformin can be effective in concentrations that are clinically achievable in humans. The expression of Pyruvate Kinase (PKM) is significantly reduced by Metformin in low glucose conditions, and our immunohistochemistry experiments showed increased expression of PKM2 in aggressive thyroid cancers.We then studied Mitotane as a metabolic agent against thyroid cancer. Initially we showed that Mitotane is cytotoxic for all thyroid cancer cell lines that were examined and that derive from all histologic types. Flow cytometry demonstrated that Mitotane causes apoptosis in thyroid cancer cells. The mechanism of action is probably induction of ER stress, that in turn causes DNA damage. We then examined the mitochondrial respiratory chain, and showed that Mitotane inhibits the mitochondrial membrane potential as well as alters the expression of the enzymes of the mitochondrial chain, mainly down regulates ATP5B. Finally, through immunohistochemistry experiments we showed that ATP5B is expressed in all human thyroid cancers, but mainly in medullary cancer. These data suggest that medullary thyroid cancer relies more heavily on mitochondria. In conclusion, the current study demonstrates that Metformin can be used against thyroid cancer, and that it is more effective in normo- or hypo-glycemic conditions. The fact that Metformin causes an oncotic cell death and that it can be combined with other metabolic agents is certainly very promising and the next step should be clinical trials in thyroid cancer patients. Similarly, Mitotane was shown in our preclinical study to be effective against thyroid cancer cell lines, and these results could form the basis for clinical trials in patients with advanced thyroid cancer.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bikas, Athanasios
  • Μπίκας, Αθανάσιος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/47442

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bikas, Athanasios; Μπίκας, Αθανάσιος. Αναζήτηση μηχανισμών για την αύξηση της αποτελεσματικότητας της μετφορμίνης ως φαρμακευτική θεραπεία για τον καρκίνο του θυρεοειδούς. National and Kapodistrian University of Athens, 2020. http://hdl.handle.net/10442/hedi/47442